In fact, plasmatic levels of VWF have been proposed as prognostic markers in patients with solid cancer [43,44,45,46], including those with HCC, in whom high levels of VWF have been correlated with increased rates of tumor recurrence after treatments [47]. This evidence concerns the gene VWF and neoplasm.